Drugs / Leritrelvir
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06160622 | Sep → Dec 2023 | impaired renal function disease | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06161259 | Sep → Oct 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06031454 | Sep → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06169085 | Aug → Sep 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-03 | Guangdong Raynovent Biotech Co., Ltd | Results 全球首个拟肽类3CL单药抗新冠病毒一类新药来瑞特韦从基础机制到临床试验学术研究成果陆续发表于国际顶刊和国际权威期刊子刊 raynovent.com ↗
来瑞特韦单药治疗可显著缩短至临床持续恢复时间，尤其是病毒核酸检测阳性72小时内服药和高病毒载量的亚组人群。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-03 | Guangdong Raynovent Biotech Co., Ltd | 全球首个拟肽类3CL单药抗新冠病毒一类新药来瑞特韦从基础机制到临床试验学术研究成果陆续发表于国际顶刊和国际权威期刊子刊 raynovent.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leritrelvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06161259 ↗ |
| Known as | RAY1216 | “A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Severe Kidney Impairment on the Pharmacokinetics, Safety and Tolerability...” NCT06160622 ↗ |
| Action | Inhibit | “It also inhibits CYP3A, CYP2C19, and OATP1B3.” PMID 42062754 ↗ May 2026 |
| Route | Oral | “Oral” NCT06160622 ↗ |